Ho Chi Lai, Wu Kwan Kit, Chen Sirong
Department of Nuclear Medicine & PET, Hong Kong Sanatorium & Hospital.
Asia Pac J Clin Oncol. 2020 Sep;16 Suppl 3:7-11. doi: 10.1111/ajco.13313.
The past decade has witnessed the rising popularity and acceptance of molecular definitions on disease management. Prostate-specific membrane antigen (PSMA), in light of its molecular nature and cytokinetic properties, has rapidly become the target for development of a variety of functional tracers for PET/CT evaluation of prostate cancer. The most commonly used PSMA-binding analog is Ga-labeled PSMA-11, which is now widely applied in both research and clinical settings. Literature data in the recent years have been enriched by a number of meta-analyses and systemic reviews on the evolving role of PSMA PET in primary diagnosis, staging, detection of biochemical recurrence after primary cancer treatment, identification, and significance of oligometastasis, as well as in restaging and treatment monitoring. Being a highly sensitive and reasonably specific molecular tracer, PSMA-binding analogs have a high potential to possess the majority of imaging characteristics required for a variety of management decisions in prostate malignancy.
在过去十年中，分子定义在疾病管理中的普及程度和认可度不断提高。前列腺特异性膜抗原（PSMA），鉴于其分子性质和细胞动力学特性，已迅速成为开发用于前列腺癌PET/CT评估的各种功能示踪剂的靶点。最常用的PSMA结合类似物是镓标记的PSMA-11，目前已广泛应用于研究和临床环境。近年来的文献数据通过大量关于PSMA PET在原发性诊断、分期、原发性癌症治疗后生化复发的检测、寡转移的识别及其意义以及再分期和治疗监测中不断演变的作用的荟萃分析和系统评价得到了丰富。作为一种高度敏感且具有合理特异性的分子示踪剂，PSMA结合类似物极有可能具备前列腺恶性肿瘤各种管理决策所需的大多数成像特征。
